Bioqual (OTCMKTS:BIOQ – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.84) EPS for the quarter, Zacks reports. Bioqual had a return on equity of 2.02% and a net margin of 1.56%.
Bioqual Price Performance
Shares of BIOQ remained flat at $37.51 on Tuesday. The company has a market capitalization of $33.38 million, a PE ratio of 46.31 and a beta of -0.19. Bioqual has a one year low of $33.00 and a one year high of $60.00. The stock has a 50-day simple moving average of $37.51 and a two-hundred day simple moving average of $38.38.
About Bioqual
Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.
Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.
Featured Articles
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
